department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Migranal · pharmadog

pharmadog
drugs
Migranal

drug

patient view →

Migranal

Marketedupdated 2mo ago

by Bausch Health US LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Migranal

generic

dihydroergotamine mesylate

indication

Migraine

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 55m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 30, 2028

~1.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

Oct 12, 2041formulationUS 11744967
Oct 12, 2041formulationUS 12102754
Dec 11, 2039formulationUS 10758532
Dec 11, 2039formulationUS 12263162
Feb 26, 2039formulationUS 10532049
Feb 26, 2039formulationUS 11304942
Feb 26, 2039method-of-use (U-4188)US 11819501
Feb 26, 2039formulationUS 12533351
Jan 4, 2039method-of-use (U-3218)US 11185497
Aug 4, 2037formulationUS 10792253
Aug 4, 2037formulationUS 11872314
Nov 5, 2036formulationUS 11266799
Mar 17, 2033formulationUS 9919117
Jan 23, 2033formulationUS 10940278
Dec 25, 2032formulationUS 10507295
Sep 5, 2032formulationUS 9550036

FDA exclusivities (1)

Apr 30, 2028NPNP1.8y

🐶 often sniffed alongside

top 2

drugdihydroergotamine mesylate1 co-mentions · 1 sources
tagRecall1 co-mentions · 1 sources

Trials studying Migranal

phase1A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adultscompletedn=44